MétaCan
Menu
Back to cohort
Record W4405600257 · doi:10.1111/dom.16050

Long‐term weight loss and cardiorenal outcomes by baseline <scp>BMI</scp> in the <scp>VERTIS CV</scp> trial

2024· article· en· W4405600257 on OpenAlexaff
Francesco Cosentino, Samuel Dagogo‐Jack, Robert Frederich, Christopher P. Cannon, David Z.I. Cherney, James P. Mancuso, Willy Wynant, Aiwen Xing, Ira Gantz, Nilo B. Cater, Richard E. Pratley

Bibliographic record

VenueDiabetes Obesity and Metabolism · 2024
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of TorontoUniversity Health Network
FundersPfizer
KeywordsMedicineWeight lossCardiorenal syndromeBody mass indexBaseline (sea)Term (time)Internal medicineCardiologyHeart failureObesity

Abstract

fetched live from OpenAlex

Abstract Aim To assess weight loss and cardiorenal outcomes by baseline body mass index (BMI) in VERTIS CV. Methods Patients with type 2 diabetes and atherosclerotic cardiovascular (CV) disease were randomized to ertugliflozin or placebo. These post hoc analyses evaluated cardiometabolic and cardiorenal outcomes (a composite of death from CV causes or hospitalization for heart failure [HHF], CV death, HHF and an exploratory composite kidney outcome including ≥40% estimated glomerular filtration rate [eGFR] decrease) by baseline BMI, using conventional clinical categories and Cox proportional hazards models. Results In total, 8246 adults were randomized (mean age 64.4 years, diabetes duration 13.0 years, BMI 32.0 kg/m 2 , 61% with BMI >30 kg/m 2 ). Absolute body weight reduction was greater with ertugliflozin versus placebo at 3 and 5 years in the overall population ( p < 0.001) and across BMI subgroups. Ertugliflozin increased the proportion of participants achieving ≥5% and ≥10% body weight reduction (ertugliflozin 34.9% and 13.6%, placebo 19.4% and 4.1%; odds ratio [95% confident interval, CI], 2.21 [1.76–2.77] and 3.65 [2.39–5.57], respectively) at 5 years. No significant difference was observed in the effect of ertugliflozin on HHF across BMI subgroups ( P interaction = 0.61). Similarly, no significant difference was observed in the effect of ertugliflozin on the kidney composite outcome across BMI subgroups ( P interaction = 0.39). Results were similar for other CV outcomes, and safety was consistent with the known ertugliflozin profile. Conclusion Weight loss was observed across baseline BMI and was sustained over 5 years of follow‐up. The effects of ertugliflozin on HHF and kidney composite were consistent across baseline BMI.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.237
Teacher spread0.229 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueDiabetes Obesity and MetabolismSame topicDiabetes Treatment and ManagementFrench-language works237,207